StreetAlpha.app
Home › Stocks › IVVD

Invivyd, Inc. (IVVD)

Healthcare
$0.51
▼ −4.67%
LAST CLOSE · NOV 17

Invivyd develops antibody therapies to prevent and treat serious viral infections, starting with COVID-19. It last closed at $0.51 on Nov 17, down 4.67% on the day. The average 12-month price target from 2 analysts is $10.00 (+1850.8% from the last close), with a high of $10.00 and a low of $10.00.

AI Auto Pilots
Is IVVD in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$60.7M
+21.3% vs a year ago
Net income
−$130.3M
−214.8% margin
EPS (diluted)
−$0.38
Free cash flow
−$134.1M
−221.0% margin
Valuation
Market cap
$151.5M
295.6M shares
P/E
–
No P/E while losing money
Price to sales
2.5
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$126.4M
At Sep 30
Shareholder equity
$150.5M
Shares outstanding
295.6M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2023: $0$0FY2023FY2024: $25.4M$25.4MFY2024FY2025: $53.4M$53.4MFY2025

From IVVD's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Last report
Nov 16
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
2 Buy
2 firms · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
2 Buy
2firms
2 Buy0 Hold0 Sell
Only 2 firms rated IVVD in the past 90 days, not enough for a consensus
Average 12-month target
$10.00
▲ 1850.8% upside

Based on 2 analysts who set a price target on IVVD in the past 90 days. The average target is $10.00, with a high of $10.00 and a low of $10.00, compared with the last close of $0.51.

Low $10.00Avg $10.00High $10.00
Blue marker: last close $0.51
Highest target$10.00
Average target$10.00
Lowest target$10.00
Latest rating changes
BTIGReiterated
Sep 14Buy$10
Cantor FitzgeraldReiterated
Aug 27Buy$10
HC Wainwright & Co.Reiterated
Jun 15Buy$10
DateFirmActionRatingPrice target
Sep 14BTIGReiteratedBuy$10
Aug 27Cantor FitzgeraldReiteratedBuy$10
Jun 15HC Wainwright & Co.ReiteratedBuy$10
Loading…

Technical Analysis

IVVD · as of the Nov 17 close · updated after every close
Downtrend, nearing oversold

The stock is 15% below its 20 day and 38% below its 50 day average. It is 110% below its 200 day average, so the longer trend is down. Momentum is fading (RSI 36), near oversold. The nearest support is the 52 week low at $0.49, and the nearest resistance the Pivot at $0.52.

Short trendBearish
Long trendBearish
MomentumFading
StretchNear oversold
VolatilityNormal, 11.5%/day
Key levels
$3.0752 week high+502.0%
$1.07200 day average+109.8%
$0.74100 day average+45.1%
$0.7150 day average+39.2%
$0.64Swing high (Oct 29)+25.5%
$0.5920 day average+15.7%
$0.55Pivot R1+7.8%
$0.52Pivot+2.0%
$0.51Last close
$0.4952 week low−3.9%
$0.48Pivot S1−5.9%
Indicators
RSI (14)35.68Weak, oversold below 30Neutral
MACD-0.04Below its signal lineBearish
Stochastic24.4Middle of its rangeNeutral
ADX (14)19.0No clear trend
Williams %R-84.9Oversold below −80, overbought above −20Oversold
CCI (20)-222.9Oversold below −100, overbought above 100Oversold
Rate of change−11.8%Change over 10 sessionsBearish
ATR (14)$0.06Typical daily range, 11.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for IVVD

What happened before

See how IVVD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow IVVD usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How IVVD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in IVVD in the last 90 days.

Loading…

See today’s whale options flow across the market →

IVVD Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Neutral
Strongly bearishNeutralStrongly bullish
  • ▲72 buying vs 48 selling
  • ▼Held by funds -4.8 pts
  • ▲Funds holding +10
  • ▼Superinvestors: 0 added, 4 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding135125+8.0%
In funds' top 10110.0%
Held by funds74.0%78.8%−4.8 pts
New / increased28 / 4433 / 38+1.4%
Reduced / sold out31 / 1726 / 45−32.4%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See IVVD institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IVVD is in one of them and how their past IVVD trades turned out.

IVVD in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered IVVD in an article yet. Here's the latest on the wider market.

About Invivyd

Invivyd is a biopharmaceutical company based in New Haven, Connecticut, that develops antibody therapies for serious viral infectious diseases. Its first authorized product, PEMGARDA, is an antibody used to help prevent COVID-19 in people who are immunocompromised and unlikely to respond well to vaccination. The company is also developing next generation COVID-19 antibodies and early candidates for diseases such as RSV and measles. Its customers are mainly patients and the healthcare providers who treat them.

Headquarters
New Haven, CT